Antibiotics Should Be One Step On FDA’s “Critical Path,” Lilly VP Says
Executive Summary
Antibiotic development is an ideal FDA "Critical Path" opportunity due to the lack of antitrust concerns surrounding the therapeutic category, Lilly VP-Scientific Affairs Gail Cassell, PhD, told the FDA Science Board Advisory Committee April 22
You may also be interested in...
Antimicrobial Development Could Benefit From Smaller Clinical Trials – FDA
Upcoming FDA guidances on antimicrobial drug development will address ways to reduce clinical trial size, Center for Drug Evaluation & Research Antimicrobial Drug Development & Resistance Initiatives Lead Medical Officer John Powers, MD, said
Antimicrobial Development Could Benefit From Smaller Clinical Trials – FDA
Upcoming FDA guidances on antimicrobial drug development will address ways to reduce clinical trial size, Center for Drug Evaluation & Research Antimicrobial Drug Development & Resistance Initiatives Lead Medical Officer John Powers, MD, said
FDA Will Publish “Critical Path” Opportunities List By Fall, Woodcock Says
FDA plans to finalize its list of "Critical Path" opportunities by early fall, Acting Deputy Commissioner for Operations Janet Woodcock said